197 related articles for article (PubMed ID: 23708302)
1. Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival.
Ozden F; Saygin C; Uzunaslan D; Onal B; Durak H; Aki H
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1373-82. PubMed ID: 23708302
[TBL] [Abstract][Full Text] [Related]
2. Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.
Brun JL; Cortez A; Lesieur B; Uzan S; Rouzier R; Daraï E
Oncol Rep; 2012 Apr; 27(4):1049-57. PubMed ID: 22200690
[TBL] [Abstract][Full Text] [Related]
3. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
[TBL] [Abstract][Full Text] [Related]
4. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
5. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis.
Katayama A; Bandoh N; Kishibe K; Takahara M; Ogino T; Nonaka S; Harabuchi Y
Clin Cancer Res; 2004 Jan; 10(2):634-40. PubMed ID: 14760086
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome.
Ara T; Fukuzawa M; Kusafuka T; Komoto Y; Oue T; Inoue M; Okada A
J Pediatr Surg; 1998 Aug; 33(8):1272-8. PubMed ID: 9722003
[TBL] [Abstract][Full Text] [Related]
7. Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer.
Reis ST; Viana NI; Iscaife A; Pontes-Junior J; Dip N; Antunes AA; Guimarães VR; Santana I; Nahas WC; Srougi M; Leite KR
Int Braz J Urol; 2015; 41(6):1088-95. PubMed ID: 26742965
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
Schwandner O; Schlamp A; Broll R; Bruch HP
Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
12. Role of matrix metalloproteinase (MMP) 2 and MMP-9 in soft tissue sarcoma.
Yang HK; Jeong KC; Kim YK; Jung ST
Clin Orthop Surg; 2014 Dec; 6(4):443-54. PubMed ID: 25436070
[TBL] [Abstract][Full Text] [Related]
13. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
Brehmer B; Biesterfeld S; Jakse G
Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
[TBL] [Abstract][Full Text] [Related]
14. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
Zhou CY; Yao JF; Chen XD
Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer.
De Cicco C; Ravasi L; Zorzino L; Sandri MT; Botteri E; Verweij F; Granchi D; de Cobelli O; Paganelli G
Curr Cancer Drug Targets; 2008 May; 8(3):199-206. PubMed ID: 18473733
[TBL] [Abstract][Full Text] [Related]
16. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
Cardillo MR; Di Silverio F; Gentile V
Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
[TBL] [Abstract][Full Text] [Related]
17. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
18. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinases (MMP-1, MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in oral submucous fibrosis.
Rajendran R; Rajeesh MP; Shaikh S; Shanthi ; Pillai MR
Indian J Dent Res; 2006; 17(4):161-6. PubMed ID: 17217211
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells.
Dong Z; Nemeth JA; Cher ML; Palmer KC; Bright RC; Fridman R
Int J Cancer; 2001 Aug; 93(4):507-15. PubMed ID: 11477554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]